Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine in Stage III Gastric Cancer
NCT06313567Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2024
- Primary completion
- Mar 2029
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in gastric cancer (GC), sponsored by Fudan University. Started Mar 2024; status: recruiting.
02
Drugs
capecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06313567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313567.